Bausch Health Companies Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名68/158位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价7.29。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Bausch Health Companies Inc评分
相关信息
行业排名
68 / 158
全市场排名
174 / 4562
所属行业
药品
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
持有
评级
7.286
目标均价
+6.83%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Bausch Health Companies Inc亮点
亮点风险
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
公司代码BHC
公司Bausch Health Companies Inc
CEOAppio (Thomas J)
网址https://www.bauschhealth.com/
常见问题
Bausch Health Companies Inc(BHC)的当前股价是多少?
Bausch Health Companies Inc(BHC)的当前股价是 7.195。
Bausch Health Companies Inc的股票代码是什么?
Bausch Health Companies Inc的股票代码是BHC。
Bausch Health Companies Inc股票的52周最高点是多少?
Bausch Health Companies Inc股票的52周最高点是11.970。
Bausch Health Companies Inc股票的52周最低点是多少?
Bausch Health Companies Inc股票的52周最低点是5.910。
Bausch Health Companies Inc的市值是多少?
Bausch Health Companies Inc的市值是2.67B。
Bausch Health Companies Inc的净利润是多少?
Bausch Health Companies Inc的净利润为-46.00M。
现在Bausch Health Companies Inc(BHC)的股票是买入、持有还是卖出?
根据分析师评级,Bausch Health Companies Inc(BHC)的总体评级为持有,目标价格为7.286。
Bausch Health Companies Inc(BHC)股票的每股收益(EPS TTM)是多少
Bausch Health Companies Inc(BHC)股票的每股收益(EPS TTM)是0.979。